191 related articles for article (PubMed ID: 36270992)
1. Lactose azocalixarene drug delivery system for the treatment of multidrug-resistant pseudomonas aeruginosa infected diabetic ulcer.
Li JJ; Hu Y; Hu B; Wang W; Xu H; Hu XY; Ding F; Li HB; Wang KR; Zhang X; Guo DS
Nat Commun; 2022 Oct; 13(1):6279. PubMed ID: 36270992
[TBL] [Abstract][Full Text] [Related]
2. Azithromycin and ciprofloxacin: a possible synergistic combination against Pseudomonas aeruginosa biofilm-associated urinary tract infections.
Saini H; Chhibber S; Harjai K
Int J Antimicrob Agents; 2015 Apr; 45(4):359-67. PubMed ID: 25604277
[TBL] [Abstract][Full Text] [Related]
3. Triple targeting host-guest drug delivery system based on lactose-modified azocalix[4]arene for tumor ablation.
Li JJ; Rong RX; Yang Y; Hu ZY; Hu B; Zhao YY; Li HB; Hu XY; Wang KR; Guo DS
Mater Horiz; 2023 May; 10(5):1689-1696. PubMed ID: 36825769
[TBL] [Abstract][Full Text] [Related]
4. In vivo evolution of antimicrobial resistance in a biofilm model of Pseudomonas aeruginosa lung infection.
Higazy D; Pham AD; van Hasselt C; Høiby N; Jelsbak L; Moser C; Ciofu O
ISME J; 2024 Jan; 18(1):. PubMed ID: 38478426
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats.
Torres BGS; Helfer VE; Bernardes PM; Macedo AJ; Nielsen EI; Friberg LE; Dalla Costa T
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28461311
[TBL] [Abstract][Full Text] [Related]
6. Fostering Innovation in the Treatment of Chronic Polymicrobial Cystic Fibrosis-Associated Infections Exploring Aspartic Acid and Succinic Acid as Ciprofloxacin Adjuvants.
Silva E; Monteiro R; Grainha T; Alves D; Pereira MO; Sousa AM
Front Cell Infect Microbiol; 2020; 10():441. PubMed ID: 32974221
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
Srivastava P; Sivashanmugam K
Infect Genet Evol; 2021 Aug; 92():104824. PubMed ID: 33774177
[TBL] [Abstract][Full Text] [Related]
8. Dual bioresponsive antibiotic and quorum sensing inhibitor combination nanoparticles for treatment of Pseudomonas aeruginosa biofilms in vitro and ex vivo.
Singh N; Romero M; Travanut A; Monteiro PF; Jordana-Lluch E; Hardie KR; Williams P; Alexander MR; Alexander C
Biomater Sci; 2019 Sep; 7(10):4099-4111. PubMed ID: 31355397
[TBL] [Abstract][Full Text] [Related]
9. In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa.
Tewes F; Bahamondez-Canas TF; Moraga-Espinoza D; Smyth HDC; Watts AB
Eur J Pharm Biopharm; 2020 Jul; 152():210-217. PubMed ID: 32442738
[TBL] [Abstract][Full Text] [Related]
10. Azithromycin-Ciprofloxacin-Impregnated Urinary Catheters Avert Bacterial Colonization, Biofilm Formation, and Inflammation in a Murine Model of Foreign-Body-Associated Urinary Tract Infections Caused by Pseudomonas aeruginosa.
Saini H; Vadekeetil A; Chhibber S; Harjai K
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031194
[No Abstract] [Full Text] [Related]
11. Ciprofloxacin conjugated gold nanorods with pH induced surface charge transformable activities to combat drug resistant bacteria and their biofilms.
Yin M; Qiao Z; Yan D; Yang M; Yang L; Wan X; Chen H; Luo J; Xiao H
Mater Sci Eng C Mater Biol Appl; 2021 Sep; 128():112292. PubMed ID: 34474843
[TBL] [Abstract][Full Text] [Related]
12. Hetero-Multivalent Targeted Liposomal Drug Delivery to Treat
Singla A; Simbassa SB; Chirra B; Gairola A; Southerland MR; Shah KN; Rose RE; Chen Q; Basharat A; Baeza J; Raina R; Chapman MJ; Hassan AM; Ivanov I; Sen A; Wu HJ; Cannon CL
ACS Appl Mater Interfaces; 2022 Sep; 14(36):40724-40737. PubMed ID: 36018830
[No Abstract] [Full Text] [Related]
13. Evaluation of Combined Ciprofloxacin and azithromycin free and nano formulations to control biofilm producing Pseudomonas aeruginosa isolated from burn wounds.
Raouf M; Essa S; El Achy S; Essawy M; Rafik S; Baddour M
Indian J Med Microbiol; 2021 Jan; 39(1):81-87. PubMed ID: 33460732
[TBL] [Abstract][Full Text] [Related]
14. Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection.
Loo CY; Lee WH; Lauretani G; Scalia S; Cipolla D; Traini D; Young P; Ong HX
Pharm Res; 2018 Feb; 35(3):50. PubMed ID: 29417313
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of sustained release ciprofloxacin microspheres against device-associated Pseudomonas aeruginosa biofilm infection in a rabbit peritoneal model.
Owusu-Ababio G; Rogers JA; Morck DW; Olson ME
J Med Microbiol; 1995 Nov; 43(5):368-76. PubMed ID: 7563002
[TBL] [Abstract][Full Text] [Related]
16. Evolution of Antibiotic Resistance in Biofilm and Planktonic Pseudomonas aeruginosa Populations Exposed to Subinhibitory Levels of Ciprofloxacin.
Ahmed MN; Porse A; Sommer MOA; Høiby N; Ciofu O
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29760140
[TBL] [Abstract][Full Text] [Related]
17. Lack of the Major Multifunctional Catalase KatA in Pseudomonas aeruginosa Accelerates Evolution of Antibiotic Resistance in Ciprofloxacin-Treated Biofilms.
Ahmed MN; Porse A; Abdelsamad A; Sommer M; Høiby N; Ciofu O
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31307984
[TBL] [Abstract][Full Text] [Related]
18. Tailoring of alginate-gelatin microspheres properties for oral Ciprofloxacin-controlled release against Pseudomonas aeruginosa.
Islan GA; Castro GR
Drug Deliv; 2014 Dec; 21(8):615-26. PubMed ID: 24401147
[TBL] [Abstract][Full Text] [Related]
19. Nano delivery systems to the rescue of ciprofloxacin against resistant bacteria "E. coli; P. aeruginosa; Saureus; and MRSA" and their infections.
Nwabuife JC; Omolo CA; Govender T
J Control Release; 2022 Sep; 349():338-353. PubMed ID: 35820538
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant effect of cranberry proanthocyanidin active fraction on antivirulent property of ciprofloxacin against Pseudomonas aeruginosa.
Vadekeetil A; Alexandar V; Chhibber S; Harjai K
Microb Pathog; 2016 Jan; 90():98-103. PubMed ID: 26620081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
